The thesis “Cost-Benefit Analysis of Malaria Interventions in Sub-Saharan Africa” examines the health and economic impacts of malaria in Ghana, a country emblematic of the region’s challenges, using a scoping review based on the PRISMA 2020 framework. Drawing from 13 peer-reviewed studies and national reports, it found that 5.6 million malaria cases in 2023 cost Ghana 2.8% of its GDP and 9% of household incomes, while contributing to high morbidity, school absenteeism, and neonatal mortality. The study highlights systemic barriers such as poverty, climate variability, weak healthcare access, and governance inefficiencies that hinder effective intervention coverage. Cost-effective interventions like ITNs, IRS, SMC, and RTS,S vaccines showed benefit-cost ratios (BCRs) between 10 and 87, with integrated approaches exceeding 100. The thesis recommends scaling up coverage to 80% through community health programs, infrastructure upgrades, and financial transparency systems to cut malaria rates by 60% and reduce GDP losses by up to 2%, aligning with multiple Sustainable Development Goals (SDGs).